Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis

被引:58
|
作者
Liao, Mingheng [1 ]
Zhu, Zexin [1 ]
Wang, Haichuan [1 ]
Huang, Jiwei [1 ]
机构
[1] Sichuan Univ, West China Hosp, Liver Transplantat Div, Dept Liver Surg, 37 Guo Xue Xiang, Chengdu 610041, Sichuan Provinc, Peoples R China
关键词
Liver cancer; hepatocellular carcinoma; surgical resection; transarterial chemoembolization; postoperative adjuvant therapy; meta-analysis; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; PORTAL-VEIN CHEMOTHERAPY; ANTICANCER DRUGS; RISK-FACTORS; THERAPY; EFFICACY; TUMOR; EMBOLIZATION; RECURRENCE; LIPIODOL;
D O I
10.1080/00365521.2017.1292365
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: To evaluate the efficacy and safety of adjuvant transarterial chemoembolization (TACE) after curative hepatectomy in improving the survival of patients with primary hepatocellular carcinoma (HCC).Methods: MEDLINE, Embase and the Cochrane Library were searched for randomized or nonrandomized studies comparing postoperative adjuvant TACE with curative resection alone. Meta-analysis was performed after converting time-event data into a hazard ratio (HR), using an inverse diversity model.Results: Eight randomized controlled trials (RCTs) and 12 retrospective studies matched the selection criteria, thereby including 3191 patients (779 in RCT, 2412 in observational studies) for the meta-analysis. The meta-analysis showed that receiving adjuvant TACE was associated with improved overall survival (OS, ln[HR]=0.70, 95%CI: 0.63-0.78, p<.001) and recurrence-free survival (RFS, ln[HR]=0.69, 95%CI: 0.63-0.76, p<.001) after curative hepatectomies. The results of observational studies were consistent with those of RCTs. Furthermore, meta-regression was utilized to detect study-level factors associated with treatment outcome. It revealed that overall survival was similar among patients treated with various combinations of chemotherapeutic drugs. Subgroup analyses demonstrated that repeated TACE interventions do not provide a higher survival benefit compared with a single course, and patients with a single tumor or tumor size5cm might stand to benefit the most from adjuvant TACE therapy.Conclusions: This meta-analysis demonstrated that postoperative adjuvant TACE could achieve higher OS and RFS than surgical resection alone. However, these results need to be validated through further high-quality clinical studies.
引用
收藏
页码:624 / 634
页数:11
相关论文
共 50 条
  • [11] Prognostic nomogram for patients with hepatocellular carcinoma underwent adjuvant transarterial chemoembolization following curative resection
    Jing, Chu-Yu
    Fu, Yi-Peng
    Zheng, Su-Su
    Yi, Yong
    Shen, Hu-Jia
    Huang, Jin-Long
    Xu, Xin
    Lin, Jia-Jia
    Zhou, Jian
    Fan, Jia
    Ren, Zheng-Gang
    Qiu, Shuang-Jian
    Zhang, Bo-Heng
    MEDICINE, 2017, 96 (11)
  • [12] Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis
    Chen, Anxin
    Li, Shijie
    Yao, Zhiyuan
    Hu, Jiahao
    Cao, Jiasheng
    Topatana, Win
    Juengpanich, Sarun
    Yu, Hong
    Shen, Jiliang
    Chen, Mingyu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 (02) : 302 - 310
  • [13] Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis
    Zhong, Jian-Hong
    Li, Le-Qun
    HEPATOLOGY RESEARCH, 2010, 40 (10) : 943 - 953
  • [14] Adjuvant Transarterial Chemoembolization after Curative Resection of Hepatocellular Carcinoma: A Non-Randomized Comparative Study
    Xi, Tao
    Lai, Eric C. H.
    Min, An-ru
    Shi, Le-hua
    Wu, Dong
    Xue, Feng
    Wang, Kui
    Yan, Zhenlin
    Xia, Yong
    Shen, Feng
    Lau, Wan Yee
    Wu, Meng-chao
    HEPATO-GASTROENTEROLOGY, 2012, 59 (116) : 1198 - 1203
  • [15] TRANSARTERIAL CHEMOEMBOLIZATION VERSUS TRANSARTERIAL RADIOEMBOLIZATION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA: A META-ANALYSIS
    Brown, Andrew
    Kassab, Ihab A.
    Chen, Vincent L.
    Townsend, Whitney A.
    Singal, Amit G.
    Parikh, Neehar D.
    HEPATOLOGY, 2019, 70 : 234A - 235A
  • [16] Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis
    Tian, Xin
    Dai, Ying
    Wang, Da-qing
    Zhang, Li
    Sui, Cheng-guang
    Meng, Fan-dong
    Jiang, Shen-yi
    Liu, Yun-peng
    Jiang, You-hong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4431 - 4440
  • [17] Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma
    Mathurin, P
    Raynard, B
    Dharancy, S
    Kirzin, S
    Fallik, D
    Pruvot, FR
    Roumilhac, D
    Canva, V
    Paris, JC
    Chaput, JC
    Naveau, S
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (10) : 1247 - 1261
  • [18] Adjuvant immunotherapy in patients with hepatocellular carcinoma who underwent curative resection: a meta-analysis
    Flores, H. F.
    Ang, E. R.
    Estanislao, N. I.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A157 - A157
  • [19] Adjuvant effect of herbal medicine on transarterial chemoembolization in patients with hepatocellular carcinoma: A systematic review and meta-analysis
    Oh, Hyeon-Muk
    Kim, Eun-Ji
    Bae, Hye-Ri
    Cho, Jung-Hyo
    Son, Chang-Gue
    Lee, Nam-Hun
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [20] Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection
    Choi, J. W.
    Ahn, S. H.
    Paik, Y. H.
    Lee, C. K.
    Lee, K. S.
    Moon, B. S.
    Han, K. -H.
    Chon, C. Y.
    Moon, Y. M.
    Kim, D. Y.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S143 - S143